South San Francisco, United States
Cellworks, a company founded in 2005, is at the forefront of Precision Drug Development and Personalized Therapy Biosimulation. With a clear focus on predicting therapy responses for individual patients and cohorts, Cellworks utilizes its breakthrough Computational Biology Model (CBM) and advanced biosimulation technology.
The company boasts a formidable trans-disciplinary team comprised of molecular biologists, cellular pathway modelers, and software technologists all dedicated to combating serious diseases and enhancing patient outcomes. This innovative approach has attracted significant backing from notable investors, including Artiman Ventures, Bering Capital, Sequoia Capital, UnitedHealth Group, and Agilent Ventures, underscoring the confidence in Cellworks' potential in revolutionizing patient care.
With its strong foundation and backing, Cellworks continues to be a promising player in the biotechnology sector, driving forward the future of precision medicine.
